Literature DB >> 23276553

Curcuminoids and resveratrol as anti-Alzheimer agents.

Oliver B Villaflores1, Ying-Ju Chen, Chih-Ping Chen, Jui-Ming Yeh, Tzong-Yuan Wu.   

Abstract

Alzheimer disease (AD) is by far the most common cause of dementia globally. This neurodegenerative disorder of the brain is chronic and progressive, characterized clinically by the deterioration in the key symptoms of behavioral and cognitive abilities. Treatment options for this disease currently are limited. Deposition of amyloid-β and tau hyperphosphorylation are cardinal pathologic features of AD that lead to the formation of neuronal plaques and neurofibrillary tangles, respectively. In addition to mounting research on herbal compounds for the treatment of AD, curcuminoids and resveratrol appear to be beneficial as anti-AD agents. Curcuminoids (curcumin and demethoxycurcumin) and resveratrol possess unique properties that make them especially worthy of further studies. This review article revisits and presents the current research done on the potential of the curcuminoids curcumin and demethoxycurcumin and the polyphenolic compound resveratrol as anti-AD compounds.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23276553     DOI: 10.1016/j.tjog.2012.09.005

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  21 in total

1.  Quantum chemical and molecular mechanics studies on the assessment of interactions between resveratrol and mutant SOD1 (G93A) protein.

Authors:  E Srinivasan; R Rajasekaran
Journal:  J Comput Aided Mol Des       Date:  2018-10-28       Impact factor: 3.686

Review 2.  Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 3.  Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside.

Authors:  Fahadul Islam; Mohamed H Nafady; Md Rezaul Islam; Susmita Saha; Salma Rashid; Aklima Akter; Md Harun- Or-Rashid; Muhammad Furqan Akhtar; Asma Perveen; Ghulam Md Ashraf; Md Habibur Rahman; Sherouk Hussein Sweilam
Journal:  Mol Neurobiol       Date:  2022-05-12       Impact factor: 5.590

4.  Resveratrol Attenuates Aβ25-35 Caused Neurotoxicity by Inducing Autophagy Through the TyrRS-PARP1-SIRT1 Signaling Pathway.

Authors:  Haoyue Deng; Man-Tian Mi
Journal:  Neurochem Res       Date:  2016-05-14       Impact factor: 3.996

Review 5.  Interactions of Amyloid-β with Membrane Proteins.

Authors:  Benita Wiatrak; Janusz Piasny; Amadeusz Kuźniarski; Kazimierz Gąsiorowski
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

Review 6.  Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute to neuroprotection in a traumatic brain injury.

Authors:  Yasuko Kitagishi; Satoru Matsuda
Journal:  Alzheimers Res Ther       Date:  2013-09-26       Impact factor: 6.982

Review 7.  Resveratrol as a therapeutic agent for Alzheimer's disease.

Authors:  Teng Ma; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Biomed Res Int       Date:  2014-11-26       Impact factor: 3.411

8.  Colorectal Adenocarcinoma Cell Culture in a Microfluidically Controlled Environment with a Static Molecular Gradient of Polyphenol.

Authors:  Roman G Szafran; Kazimierz Gąsiorowski; Benita Wiatrak
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411

9.  Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Authors:  Angel Agis-Torres; Monica Sölhuber; Maria Fernandez; J M Sanchez-Montero
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

10.  Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia.

Authors:  Xingrong Ma; Zhikun Sun; Yanru Liu; Yanjie Jia; Boai Zhang; Jiewen Zhang
Journal:  Neural Regen Res       Date:  2013-08-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.